NCT02722798View on ClinicalTrials.gov

A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

October 31, 2020

Conditions
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Interventions
DRUG

KRN23

Doses may be titrated to achieve the target peak serum phosphorus range

Trial Locations (3)

Unknown

Osaka

Tokyo

Seoul

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02722798 - A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | Biotech Hunter | Biotech Hunter